ROCKWELL MEDICAL, INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
RMTI$7.31-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 202 and
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and par value amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Cash and Cash Equivalents | $15,662 | $8,983 |
| Investments Available-for-Sale | 5,940 | 1,952 |
| Accounts Receivable, net of a reserve of nil for 2024 and $81 for 2023 | 8,291 | 10,901 |
| Inventory, net | 5,778 | 5,871 |
| Prepaid and Other Current Assets | 1,359 | 1,063 |
| Total Current Assets | 37,030 | 28,770 |
| Property and Equipment, net | 5,785 | 6,402 |
| Inventory - Non-Current | 178 | 178 |
| Right of Use Assets - Operating, net | 3,215 | 2,713 |
| Right of Use Assets - Financing, net | 1,344 | 1,903 |
| Intangible Assets, net | 10,207 | 10,759 |
| Goodwill | 921 | 921 |
| Other Non-Current Assets | 528 | 527 |
| Total Assets | $59,208 | $52,173 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Accounts Payable | $2,869 | $4,516 |
| Accrued Liabilities | 6,275 | 7,149 |
| Deferred Consideration - Current | 2,371 | 2,500 |
| Lease Liabilities - Operating - Current | 1,566 | 1,381 |
| Lease Liabilities - Finance - Current | 599 | 558 |
| Deferred License Revenue - Current | 46 | 46 |
| Insurance Financing Note Payable | 268 | 244 |
| Customer Deposits | 97 | 243 |
| Total Current Liabilities | 14,091 | 16,637 |
| Lease Liabilities - Operating - Long-Term | 1,699 | 1,433 |
| Lease Liabilities - Finance - Long-Term | 931 | 1,530 |
| Term Loan - Long-Term, Net of Issuance Costs | 8,472 | 8,293 |
| Deferred License Revenue - Long-Term | 429 | 475 |
| Deferred Consideration - Long-Term | 1,000 | 2,500 |
| Long Term Liability - Other | — | 14 |
| Total Liabilities | 26,622 | 30,882 |
| Commitments and Contingencies (See Note 15) | ||
| Stockholders’ Equity: | ||
| Preferred Stock, $0.0001 par value, 2,000,000 shares authorized, 15,000 shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common Stock, $0.0001 par value, 170,000,000 shares authorized, 34,056,920 and 29,130,607 shares issued and outstanding at December 31, 2024 and 2023, respectively | 3 | 3 |
| Additional Paid-in Capital | 430,207 | 418,487 |
| Accumulated Deficit | (397,678) | (397,198) |
| Accumulated Other Comprehensive Income (Loss) | 54 | (1) |
| Total Stockholders’ Equity | 32,586 | 21,291 |
| Total Liabilities and Stockholders’ Equity | $59,208 | $52,173 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.